Search Within

Gopakumar Vasudeva Iyer

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (202)
  2. Journal Article (118)
  3. Review (11)
  4. Book Section (5)
  5. Editorial (3)
  6. Correspondence (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (342)
  2. Genitourinary Oncology Service (342)
  3. Solid Tumor Oncology Division (342)
  4. Department of Pathology and Laboratory Medicine (214)
  5. GSK Faculty (194)
  6. Human Oncology and Pathogenesis Program (191)

More Groups

People
  1. Hikmat Al-Ahmadie (182)
  2. David Solit (181)
  3. Jonathan Rosenberg (169)
  4. Dean Bajorin (160)
  5. Bernard Bochner (129)
  6. Michael Berger (102)

More People

Years
  1. 2025 (14)
  2. 2024 (41)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (34)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (117)
  2. Laboratory Investigation (27)
  3. Modern Pathology (20)
  4. Cancer Research (17)
  5. Clinical Cancer Research (14)
  6. Annals of Oncology (13)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Nature Publishing Group (43)
  3. American Association for Cancer Research (34)
  4. Elsevier Inc. (33)
  5. Nature Research (20)
  6. Oxford University Press (15)

More Publishers

Results (342)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (precision I)
    Meeting Abstract

    Rodon, J.; Demeure, M.; Deming, D.; Federman, N.; McKean, M.; Lee, E.; Spira, A.; Kwiatkowski, D.; Hussein, M.; Gordon, E.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Inactivation mutations of KMT2C/D license a molecular "field effect" and prime the urothelium for tumorigenesis
    Meeting Abstract

    Wang, N.; Pachai, M. R.; Li, D.; Lee, C.; Warda, S.; Xie, G.; Qian, C.; Wong, W. P. E.; Yan, J.; Hu, W.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
    Meeting Abstract

    Koshkin, V. S.; Powles, T. B.; Iyer, G.; Loriot, Y.; Drakaki, A.; Martinez, I. D.; De Santis, M.; Retz, M.; Jain, R. K.; Chan, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Inherited germline cancer susceptibility gene variants in individuals with non-muscle-invasive bladder cancer
    Journal Article

    Pietzak, E. J.; Whiting, K.; Srinivasan, P.; Bandlamudi, C.; Khurram, A.; Joseph, V.; Walasek, A.; Bochner, E.; Clinton, T.; Almassi, N.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Genomic heterogeneity as a barrier to precision oncology in urothelial cancer
    Journal Article

    Clinton, T. N.; Chen, Z.; Wise, H.; Lenis, A. T.; Chavan, S.; Donoghue, M. T. A.; Almassi, N.; Chu, C. E.; Dason, S.; Rao, P.; more...
    Cell Reports (2022)

    Fulltext@MSK | Save
  • Entitäten-unabhängige sicherheit und wirksamkeit von erdafitinib bei patienten mit fortgeschrittenen soliden tumoren mit präspezifizierten genomischen fgfraberrationen (RAGNAR Interimanalyse)
    Meeting Abstract

    Schuler, M.; Loriot, Y.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P)
    Meeting Abstract

    McConkey, D. J.; Choi, W.; Halabi, S.; Luo, B.; Al-Ahmadie, H. A.; Rosenberg, J. E.; Mountain, J.; Regazzi, A. M.; Fong, M.; Iyer, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results
    Meeting Abstract

    Loriot, Y.; Schuler, M. H.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314
    Meeting Abstract

    Iyer, G.; Tangen, C.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L. C.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M.; McConkey, D. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save